Men with prostate cancer that doesn't respond to hormone therapy live much shorter lives after spine surgery than those whose cancer still responds to hormone treatment.
Scientific Claim
Patients with hormone-refractory prostate cancer undergoing surgical decompression for spinal cord compression have a median overall survival of 6.6 months, compared to 16.3 months for those with hormone-sensitive disease, indicating a substantially shorter life expectancy in the hormone-refractory subgroup.
Original Statement
“Median overall survival for HRPC patients was 6.6 mo (95% confidence interval [CI]: 5.6-8.6) while the median overall survival for hormone-sensitive patients was 16.3 mo (95% CI: 4.0-26.6).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim reports observed median survival times from a retrospective cohort, which is appropriate for this study design. Survival differences are descriptive associations, not causal claims.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aThe pooled median overall survival difference between hormone-refractory and hormone-sensitive prostate cancer patients after surgical decompression for spinal cord compression.
The pooled median overall survival difference between hormone-refractory and hormone-sensitive prostate cancer patients after surgical decompression for spinal cord compression.
What This Would Prove
The pooled median overall survival difference between hormone-refractory and hormone-sensitive prostate cancer patients after surgical decompression for spinal cord compression.
Ideal Study Design
A systematic review and meta-analysis of all published studies reporting median overall survival after surgical decompression for spinal cord compression in metastatic prostate cancer, stratified by hormone sensitivity status, including at least 15 studies with >1000 total patients and standardized definitions of hormone resistance and survival endpoints.
Limitation: Cannot account for differences in postoperative treatments or patient selection across studies.
Prospective Cohort StudyLevel 2bThe independent effect of hormone resistance on survival after surgical decompression, adjusting for age, performance status, and metastatic burden.
The independent effect of hormone resistance on survival after surgical decompression, adjusting for age, performance status, and metastatic burden.
What This Would Prove
The independent effect of hormone resistance on survival after surgical decompression, adjusting for age, performance status, and metastatic burden.
Ideal Study Design
A prospective multicenter cohort study of 500 patients undergoing surgical decompression for spinal cord compression from prostate cancer, with standardized hormone sensitivity assessment, baseline performance status, and postoperative treatment protocols, followed for 24 months to determine median survival by hormone status.
Limitation: Cannot prove hormone resistance directly causes shorter survival; confounding factors like tumor biology may be responsible.
Case-Control StudyLevel 3bIn EvidenceWhether hormone-refractory status is a stronger predictor of death within 12 months after surgery than other clinical variables.
Whether hormone-refractory status is a stronger predictor of death within 12 months after surgery than other clinical variables.
What This Would Prove
Whether hormone-refractory status is a stronger predictor of death within 12 months after surgery than other clinical variables.
Ideal Study Design
A matched case-control study comparing 200 patients who died within 12 months post-surgery (cases) with 200 survivors (controls), matched for age and surgical procedure, analyzing hormone sensitivity, PSA doubling time, and number of metastatic sites as predictors of early mortality.
Limitation: Retrospective design limits ability to establish temporal sequence or control for unmeasured confounders.
Evidence from Studies
Supporting (1)
Surgical Decompression of High-Grade Spinal Cord Compression from Hormone Refractory Metastatic Prostate Cancer
This study looked at prostate cancer patients who had surgery to relieve spinal cord pressure and found that those whose cancer no longer responded to hormone therapy lived much shorter lives—about 6.6 months—compared to those whose cancer still responded to hormones, who lived about 16.3 months. This matches exactly what the claim says.